Answers are grounded in this paper and cite their sources.
Background: Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown. Methods: We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained before and after at least 3 months of therapy with budesonide in 16 pediatric EE subjects. In addition, we investigated whether corticosteroid therapy modulated vascular activation (expression of VCAM‐1; level of interstitial edema), TGFβ 1 activation (levels of TGFβ 1 , phosphorylated Smad2/3), and performed a pilot analysis of a polymorphism in the TGFβ 1 promoter in relation to EE subjects who had reduced remodeling with budesonide therapy. Results: EE subjects were stratified based on the presence ( n = 9) or absence ( n = 7) of decreased epithelial eosinophilia following budesonide. Patients with residual eosinophil counts of ≤7 eosinophils per high power field in the epithelial space (responders) demonstrated significantly reduced esophageal remodeling with decreased fibrosis, TGFβ 1 and pSmad2/3 positive cells, and decreased vascular activation in association with budesonide therapy. Responders were more likely to have a CC genotype at the −509 position in the TGFβ 1 promoter. Conclusions: Reductions in epithelial eosinophils following budesonide therapy were associated with significantly reduced esophageal remodeling.
No takes yet. Share an insight, caveat, or question.
Aceves et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: